Lexaria Bioscience Corp.
Lexaria Bioscience is a biotechnology company that develops and licenses DehydraTECH, a patented technology for enhancing the bioavailability of active pharmaceutical ingredients in orally ingestible products. The technology combines active ingredients with long-chain fatty acid-rich triglyceride oils and carrier compounds, and can be used with molecules including GLP-1 and GIP drugs, CBD, nicotine, vitamins and pain medications. Lexaria focuses primarily on pharmaceutical products and also applies the technology to nutraceuticals, foods, beverages and consumer products. Lexaria earns money through licenses and royalties on sales of products that use DehydraTECH, and provides licensees with advice on integrating the technology into their products. Its research centers on formulations for diabetes, weight loss and hypertension, among other therapeutic areas. The company is headquartered in Kelowna, British Columbia, Canada.
No enriched coverage for $LEXX in the last 7 days.
No SEC Form 4 filings for $LEXX in the last 30 days.
See all $LEXX insider activity →Lexaria Bioscience (NASDAQ: LEXX) announced a partnership with an unnamed pharmaceutical company to test its DehydraTECH technology with proprietary molecules. The agreement could lead to a licensing deal if successful. Lexaria was introduced to the partner by Liberi Group. The company holds 70 granted patents for its drug delivery technology.
Lexaria Bioscience (NASDAQ: LEXX) received four patents for its DehydraTECH drug delivery technology in the U.S., Canada, and Europe, covering treatments for diabetes, hypertension, and epilepsy. The company now holds 70 granted patents globally, with more pending. CEO Richard Christopher highlighted the value of its intellectual property for business development.
Lexaria Bioscience (NASDAQ: LEXX) completed enrollment for its Human Pilot Study #7, evaluating oral DehydraTECH-semaglutide against Novo's Wegovy. The study assesses safety, tolerability, and pharmacokinetic properties over five weeks, with dosing expected to complete in mid-November. This is the first multi-dose, multi-week study of SNAC-inclusive formulations.
Recent LEXX coverage spans technology, corporate actions and financial news.
The partnership could unlock future licensing revenue if the evaluation succeeds.
The new patents enhance Lexaria's IP portfolio, potentially improving its drug delivery technology valuation.
Enrollment completion signals progress toward potential FDA filing and could boost investor sentiment.
Preclinical data shows promising brain absorption for a CBD formulation and non‑inferior plasma exposure for semaglutide.
Preclinical data suggests a significant boost in brain uptake, which could de‑risk future human trials for Lexaria's oral delivery platform.
AlphAI scores every news story that mentions LEXX with an AI model for sentiment and relevance, and aggregates insider trades from Lexaria Bioscience Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lexaria Bioscience (NASDAQ: LEXX) announced a partnership with an unnamed pharmaceutical company to test its DehydraTECH technology with proprietary molecules. The agreement could lead to a licensing deal if successful. Lexaria was introduced to the partner by Liberi Group. The company holds 70 granted patents for its drug delivery technology.
Lexaria Bioscience (NASDAQ: LEXX) received four patents for its DehydraTECH drug delivery technology in the U.S., Canada, and Europe, covering treatments for diabetes, hypertension, and epilepsy. The company now holds 70 granted patents globally, with more pending. CEO Richard Christopher highlighted the value of its intellectual property for business development.
Lexaria Bioscience (NASDAQ: LEXX) completed enrollment for its Human Pilot Study #7, evaluating oral DehydraTECH-semaglutide against Novo's Wegovy. The study assesses safety, tolerability, and pharmacokinetic properties over five weeks, with dosing expected to complete in mid-November. This is the first multi-dose, multi-week study of SNAC-inclusive formulations.
Lexaria Bioscience reported animal study results showing DehydraTECH-CBD formulations matched a reference in blood absorption and one achieved 566% higher mean brain levels at 8 hours. DehydraTECH-semaglutide showed non-inferior plasma exposure to reference but brain levels were below assay quantitation.
Lexaria Bioscience reported a 566% improvement in brain absorption for its DHT-CBD formulation in an animal study. The company also noted non-inferior blood plasma absorption for DHT-SEMA. According to the company, these results reinforce its oral delivery platform for CBD and GLP-1 assets. The next major catalyst would likely involve human data or regulatory milestones.
Lexaria Bioscience Corp. (NASDAQ: LEXX) announced a strong cash position following a $7.9M tax refund and institutional financing at $12.92/share. The company has $4.60/share in cash, extending its runway through 2027. CEO Rich Christopher noted recent stock price pressure but plans to execute business strategy. Lexaria expects to reduce R&D costs in 2027 through partnerships.
Lexaria Bioscience Corp. (NASDAQ: LEXX) closed the exercise of warrants, raising $5.9 million. The company issued new Series A and B warrants. Proceeds will be used for working capital and corporate purposes. H.C. Wainwright & Co. acted as the placement agent.
Lexaria Bioscience Corp. (LEXX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EXHIBIT 99.1 Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds Tuesday, 08 September 2026 08:00 AM Topic: Financing KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Le
U.S. stocks fell Tuesday, with the Dow Jones dropping 450 points. The NFIB Small Business Optimism Index declined to 98.7 in August. PDS Biotechnology (PDSB) shares surged 178% after raising $22.55 million in equity funding. Energy shares rose 1.4%, while healthcare stocks fell 2.2%.
Lexaria Bioscience Corp. (NASDAQ: LEXX) received a AUD$3.67 million (USD$2.6 million) tax rebate from the Australian Tax Office for its 2025 R&D study. The funds will support future R&D in Australia, according to the company. The rebate was not included in previous financial statements but will be accounted for in the upcoming 10-K filing.
